These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

401 related items for PubMed ID: 25585592

  • 1. Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus.
    Rys P, Wojciechowski P, Rogoz-Sitek A, Niesyczyński G, Lis J, Syta A, Malecki MT.
    Acta Diabetol; 2015 Aug; 52(4):649-62. PubMed ID: 25585592
    [Abstract] [Full Text] [Related]

  • 2. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T, Engler J, Siebenhofer A, Jeitler K, Berghold A, Horvath K.
    Cochrane Database Syst Rev; 2020 Nov 09; 11(11):CD005613. PubMed ID: 33166419
    [Abstract] [Full Text] [Related]

  • 3. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
    Hemmingsen B, Metzendorf MI, Richter B.
    Cochrane Database Syst Rev; 2021 Mar 04; 3(3):CD013498. PubMed ID: 33662147
    [Abstract] [Full Text] [Related]

  • 4. A comparison of biphasic insulin aspart and insulin glargine administered with oral antidiabetic drugs in type 2 diabetes mellitus--a systematic review and meta-analysis.
    Rys P, Wojciechowski P, Siejka S, Małecki P, Hak L, Malecki MT.
    Int J Clin Pract; 2014 Mar 04; 68(3):304-13. PubMed ID: 24471814
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of basal insulins in people with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials.
    Dehghani M, Sadeghi M, Barzkar F, Maghsoomi Z, Janani L, Motevalian SA, Loke YK, Ismail-Beigi F, Baradaran HR, Khamseh ME.
    Front Endocrinol (Lausanne); 2024 Mar 04; 15():1286827. PubMed ID: 38586456
    [Abstract] [Full Text] [Related]

  • 6. Influence of baseline glycemia on outcomes with insulin glargine use in patients uncontrolled on oral agents.
    Banerji MA, Baron MA, Gao L, Blonde L.
    Postgrad Med; 2014 May 04; 126(3):111-25. PubMed ID: 24918797
    [Abstract] [Full Text] [Related]

  • 7. Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy.
    Owens DR, Traylor L, Mullins P, Landgraf W.
    Diabetes Res Clin Pract; 2017 Feb 04; 124():57-65. PubMed ID: 28092788
    [Abstract] [Full Text] [Related]

  • 8. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P, Cooper J, Bregnhøj J, Pedersen CB.
    Clin Ther; 2008 Nov 04; 30(11):1976-87. PubMed ID: 19108786
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of the incidence and risk of hypoglycemic coma associated with selection of basal insulin in the treatment of diabetes: a Finnish register linkage study.
    Haukka J, Hoti F, Erästö P, Saukkonen T, Mäkimattila S, Korhonen P.
    Pharmacoepidemiol Drug Saf; 2013 Dec 04; 22(12):1326-35. PubMed ID: 24150837
    [Abstract] [Full Text] [Related]

  • 10. Comparison of safety and efficacy of insulin glargine and neutral protamine hagedorn insulin in older adults with type 2 diabetes mellitus: results from a pooled analysis.
    Lee P, Chang A, Blaum C, Vlajnic A, Gao L, Halter J.
    J Am Geriatr Soc; 2012 Jan 04; 60(1):51-9. PubMed ID: 22239291
    [Abstract] [Full Text] [Related]

  • 11. Comparative effectiveness and safety of different basal insulins in a real-world setting.
    Ji L, Zhang P, Zhu D, Lu J, Guo X, Wu Y, Li X, Ji J, Jia W, Yang W, Zou D, Zhou Z, Gao Y, Garg SK, Pan C, Weng J, Paul SK, ORBIT study group.
    Diabetes Obes Metab; 2017 Aug 04; 19(8):1116-1126. PubMed ID: 28230322
    [Abstract] [Full Text] [Related]

  • 12. Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia.
    Johansen OE, Vanberg PJ, Kilhovd BK, Jørgensen AP.
    Vasc Health Risk Manag; 2009 Aug 04; 5(1):121-8. PubMed ID: 19436668
    [Abstract] [Full Text] [Related]

  • 13. Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial.
    Rosenstock J, Fonseca V, Schinzel S, Dain MP, Mullins P, Riddle M.
    J Diabetes Complications; 2014 Aug 04; 28(5):742-9. PubMed ID: 24856612
    [Abstract] [Full Text] [Related]

  • 14. Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin.
    Pieber TR, Draeger E, Kristensen A, Grill V.
    Diabet Med; 2005 Jul 04; 22(7):850-7. PubMed ID: 15975098
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets.
    Cannon AJ, Bargiota A, Billings L, Hunt B, Leiter LA, Malkin S, Mocarski M, Ranthe MF, Schiffman A, Doshi A.
    J Manag Care Spec Pharm; 2020 Feb 04; 26(2):143-153. PubMed ID: 31856636
    [Abstract] [Full Text] [Related]

  • 16. A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus.
    Pan C, Gross JL, Yang W, Lv X, Sun L, Hansen CT, Xu H, Wagner R.
    Drugs R D; 2016 Jun 04; 16(2):239-49. PubMed ID: 27098525
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and risk of hypoglycemia with use of insulin glargine or comparators in patients with cardiovascular risk factors.
    Blonde L, Baron MA, Zhou R, Banerji MA.
    Postgrad Med; 2014 May 04; 126(3):172-89. PubMed ID: 24918802
    [Abstract] [Full Text] [Related]

  • 18. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.
    Health Technol Assess; 2010 Jul 04; 14(36):1-248. PubMed ID: 20646668
    [Abstract] [Full Text] [Related]

  • 19. Comparison of Hypoglycemia and Safety Outcomes With Long-Acting Insulins Versus Insulin NPH in Pregestational and Gestational Diabetes.
    Sleeman A, Odom J, Schellinger M.
    Ann Pharmacother; 2020 Jul 04; 54(7):669-675. PubMed ID: 31893932
    [Abstract] [Full Text] [Related]

  • 20. Comparing the efficacy and safety of insulin detemir versus neutral protamine hagedorn insulin in treatment of diabetes during pregnancy: a randomized, controlled study.
    Ji J, He Z, Yang Z, Mi Y, Guo N, Zhao H, Gao J, Ma Z, Luo X, Han Z.
    BMJ Open Diabetes Res Care; 2020 Apr 04; 8(1):. PubMed ID: 32265255
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.